Pfizer Investor Presentation — August 2018

Document content

Tafamidis Analyst Briefing

1 2 Forward Looking Statements

•This presentation includes forward- looking statements about, among other things, a

potential indication for Tafamidis for the treatment of transthyretin cardiomyopathy and

Pfizer’s rare disease portfolio, including their potential benefits, that are subject to

substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these

factors can be found in Pfizer’s Annual Report on Form 10 -K for the fiscal year ended

December 31, 2017 and in our subsequent reports on Form 10 -Q, including in the

sections thereof captioned “Risk Factors” and “Forward -Looking Information and Factors

that May Affect Future Results”, as well as in our subsequent reports on Form 8 -K, all of

which are filed with the US Securities and Exchange Commission (SEC) and available at

www.sec.gov and www.pfizer.com

• The forward -looking statements in this presentation speak only as of the original date of

this presentation, and we undertake no obligation to update or revise any of these

statements. 3 John Young

Pfizer Innovative Health 4 Pfizer Rare Disease: Growing Clinical Potential

*Pipeline status as of July31, 2018 † This compound is an investigational drug and is not approved by the FDA ‡Not approved in the United States. It is currently in registration in the United States

Duchenne Muscular Dystrophy (DMD) 5 Patients in Need: ATTR -CM is Currently Poorly Diagnosed

• ATTR -CM is a rare,

universally fatal disease associated with restrictive cardiomyopathy and progressive heart failure

• Survival in untreated p

atients is 2.5 years